Janus Kinase Inhibitors: all 1,428 studies that test it

Page 10 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.

• A SHR0302 BA Study on Healthy SubjectsCompletedNCT06202612Phase 1
• Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia RheumaticaCompletedNCT06172361Phase 3
• A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoActive, not recruitingNCT06163326Phase 3
• Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept StudyActive, not recruitingNCT06158113Phase 2
• Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia AreataCompletedNCT06157905Early Phase 1
• An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604CompletedNCT06157255Phase 1
• A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory GenodermatosesCompletedNCT06136403Phase 2
• A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With VitiligoActive, not recruitingNCT06118411Phase 3
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)Active, not recruitingNCT06113471Phase 3
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)Active, not recruitingNCT06113445Phase 3
• A Study of TAK-279 in Healthy Chinese AdultsCompletedNCT06111547Phase 1
• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment PeriodCompletedNCT06108544Phase 3
• A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid ArthritisCompletedNCT06099535Phase 2
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)Active, not recruitingNCT06095128Phase 4
• A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male ParticipantsCompletedNCT06088264Phase 1
• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of TreatmentCompletedNCT06088043Phase 3
• A Study of LNK01001 Capsule in Patients With Ankylosing SpondylitisCompletedNCT06085534Phase 2
• A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic DermatitisCompletedNCT06085521Phase 2
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2Active, not recruitingNCT06072183Phase 3
• Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR InhibitorActive, not recruitingNCT06057571Phase 2
• Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy SubjectsCompletedNCT06043739Phase 1
• A Study to Evaluate Drug-Drug Interaction of TQ05105 TabletsCompletedNCT06024915Phase 1
• Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABACompletedNCT06020014Phase 2
• A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand EczemaCompletedNCT06004050Phase 3
• A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy AdultsCompletedNCT05995249Phase 1
• A Study of TAK-279 in Adults With or Without Kidney ProblemsCompletedNCT05992155Phase 1
• To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult SubjectsCompletedNCT05982106Phase 1
• A Study of TAK-279 in Adults With or Without Liver DamageCompletedNCT05976321Phase 1
• Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic DermatitisCompletedNCT05969730Not applicable
• Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusActive, not recruitingNCT05966480Phase 2
• POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUTerminatedNCT05953688Phase 2
• Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaActive, not recruitingNCT05948475Phase 3
• A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeActive, not recruitingNCT05946941Phase 3
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT05936359Phase 1
• Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum DisordersWithdrawnNCT05909943Phase 1/2
• The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor PneumoniaCompletedNCT05899725Not applicable
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyActive, not recruitingNCT05889182Phase 3
• Ritlecitinib in CTCLTerminatedNCT05879458Phase 2
• REVERSE-Long COVID-19 With Baricitinib StudyWithdrawnNCT05858515Phase 3
• A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusCompletedNCT05856448Phase 2
• To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative BioavailabilityCompletedNCT05856058Phase 1
• Baricitinib in Idiopathic Granulomatous MastitisActive, not recruitingNCT05852171Phase 2
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaActive, not recruitingNCT05851443Phase 2
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusActive, not recruitingNCT05843643Phase 3
• Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical TrialStatus unknownNCT05827497Phase 4
• Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
• Deucravacitinib in PGWithdrawnNCT05821374Early Phase 1
• Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT05814627Phase 3
• Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT05792462Phase 1
• A Study Evaluating the Effect of Filgotinib in Participants With Active Axial SpondyloarthritisActive, not recruitingNCT05785611Phase 3
• Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.Active, not recruitingNCT05782907Phase 3
• Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)Active, not recruitingNCT05743244Phase 2
• Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisActive, not recruitingNCT05739435Phase 2
• Janus Kinase Inhibition in SarcoidosisCompletedNCT05696795Phase 2
• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisCompletedNCT05695950Phase 2
• VTX958 for the Treatment of Moderately to Severely Active Crohn's DiseaseTerminatedNCT05688852Phase 2
• Use of Baricitenib to Maintain of RemissionStatus unknownNCT05686746Phase 2/3
• Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host DiseaseCompletedNCT05663827Phase 3
• Therapies for Down Syndrome Regression DisorderCompletedNCT05662228Phase 2
• Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid ArthritisCompletedNCT05660655Phase 4
• Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint InhibitorsWithdrawnNCT05660421Phase 2
• Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male SubjectsCompletedNCT05657613Phase 1
• VTX958 Versus Placebo for the Treatment of Moderate to Severe PsoriasisTerminatedNCT05655299Phase 2
• Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in RemissionCompletedNCT05636293Phase 2
• Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on HemodialysisCompletedNCT05624723Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentCompletedNCT05624710Phase 1
• De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) ProphylaxisActive, not recruitingNCT05622318Phase 2
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT05620836Phase 3
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT05620823Phase 3
• A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusActive, not recruitingNCT05620407Phase 3
• A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT05617677Phase 3
• A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy ParticipantsCompletedNCT05615012Phase 1
• To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 WeeksStatus unknownNCT05606107Phase 4
• Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With DupilumabCompletedNCT05602207Phase 4
• Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT ModelCompletedNCT05600855Phase 2
• A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) TranquilloCompletedNCT05583526Phase 3
• A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female ParticipantsCompletedNCT05579574Phase 1
• A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese DescentCompletedNCT05546151Phase 1
• Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)TerminatedNCT05524857Phase 1
• Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)CompletedNCT05524311Phase 2
• A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior UveitisCompletedNCT05523765Phase 2
• Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic DermatitisCompletedNCT05487963Phase 1/2
• Drug-drug Interactions Between AZD4205 and Itraconazole/CarbamazepineCompletedNCT05486949Phase 1
• Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand EczemaCompletedNCT05486117Phase 1
• Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy SubjectsCompletedNCT05478772Phase 1
• Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia AreataActive, not recruitingNCT05470413Phase 3
• Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543CompletedNCT05468749Phase 1
• Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543CompletedNCT05467722Phase 1
• Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy SubjectsCompletedNCT05467709Phase 1
• Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy VolunteersCompletedNCT05467696Phase 1
• A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in MyelofibrosisStatus unknownNCT05447260Phase 4
• Baricitinib for Steroid-resistant/Relapse Immune ThrombocytopeniaStatus unknownNCT05446831Phase 2
• Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT05440942Phase 1
• A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisCompletedNCT05437263Phase 3
• Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic DermatitisCompletedNCT05432596Phase 2
• Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy ParticipantsCompletedNCT05431634Phase 1
• Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans SyndromeStatus unknownNCT05413356Phase 2
• Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory MyopathiesStatus unknownNCT05400889Phase 2
• A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy VolunteersCompletedNCT05392127Phase 1
• The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis PatientsWithdrawnNCT05379322Phase 3

← Janus Kinase Inhibitors overview